Last updated 2026-09-04
- Went public on NASDAQ (MBOT), Mar 1992
- Acquired NitiLoop, Oct 2022
- Acquired CardioSert for $370k, May 2018
Total raised
$148.3M
Last: Public Offering 2025-10
Stage
Public
Founded
2010
Headcount
58
HQ
Hingham, United States
Sector
Medical Equipment
About
Microbot Medical Inc. is a medical device company focused on transforming endovascular procedures through advanced robotic technology. The company specializes in the research, design, development, and commercialization of transformational micro-robotics medical technologies, leveraging natural and artificial lumens within the human body. Its flagship product, the LIBERTY® Endovascular Robotic System, is the first single-use, remotely operated robotic solution designed for precision, efficiency, and provider safety in various endovascular interventional procedures. Microbot Medical also has other technological platforms like ViRob™ and TipCAT™ and is developing products such as the Self Cleaning Shunt (SCS™) for hydrocephalus. The company operates in the US and Israel.
Funding history · 12 rounds · $148.3M total
19 events/rounds · $148.3M Total Funding: $227.2M in Public Equity
Apr 2026
Follow-on PO
$39.2M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Oct 2025
PIPE
$2.8M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Sep 2025
PIPE
$29.7M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Aug 2025
PIPE
$7.6M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Apr 2025
PIPE
$2.3M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Feb 2025
Follow-on PO
$15.6M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Feb 2025
PIPE
$13.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Feb 2025
Follow-on PO
$27.4M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Jan 2025
PIPE
$7.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Jun 2023
Grant
Undisclosed
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Jan 2019
Follow-on PO
$3.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
2012
Acquisitions · 2
Oct 2022
NitiLoop
Undisclosed
May 2018
CardioSert
$370K
Headcount over time
58 employees (2026-09) · 1 point
Offices
Hingham, United States · HQ / main office
Show all offices (1 more)
- Braintree, United States
Q&A
- What significant regulatory milestone did Microbot Medical achieve in September 2025?
- In September 2025, Microbot Medical Inc. received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System, allowing commercialization in the U.S. market.
- What was the outcome of Microbot Medical's pivotal human clinical trial for the LIBERTY Endovascular Robotic Surgical System?
- In October 2024, Microbot Medical announced the successful completion of its pivotal human clinical trial for the LIBERTY Endovascular Robotic Surgical System, accelerating its go-to-market strategy for a Q2 2025 commercial launch.
- What strategic partnership did Microbot Medical form in August 2024 to advance telesurgery?
- In August 2024, Microbot Medical Inc. signed a Phase 2 collaboration agreement with Corewell Health to advance remote telesurgery for endovascular procedures using the LIBERTY Endovascular Robotic System.
- What quality certification did Microbot Medical receive in August 2024?
- In August 2024, Microbot Medical Inc. received ISO 13485:2016 certification for its quality management system, a crucial step for commercialization and regulatory compliance in the EU and US.
- What was the outcome of Microbot Medical's GLP pivotal pre-clinical study for the LIBERTY Endovascular Robotic Surgical System in December 2023?
- In December 2023, Microbot Medical Inc. successfully completed its GLP pivotal pre-clinical study for the LIBERTY Endovascular Robotic Surgical System, meeting all study objectives and paving the way for human clinical trials.
- What was the purpose of Microbot Medical's manufacturing agreement with B.Y. Medimor Ltd. in August 2023?
- In August 2023, Microbot Medical Inc. signed a manufacturing agreement with B.Y. Medimor Ltd. for the production of its LIBERTY Robotic Surgical System, supporting its transition to clinical trials and commercialization.
- What was the outcome of Microbot Medical's extended pre-clinical animal study for the LIBERTY Surgical Robotic System in May 2023?
- In May 2023, Microbot Medical Inc. achieved a 100% success rate in an extended joint pre-clinical animal study for its LIBERTY Surgical Robotic System, with six European interventional radiologists performing 48 catheterizations.
- What was the impact of Microbot Medical's Core Business Focus Program and cost restructuring plan announced in May 2023?
- In May 2023, Microbot Medical Inc. announced a Core Business Focus Program and cost restructuring plan to prioritize its LIBERTY Robotic Surgical System, which involved eliminating non-core technology expenses and reducing positions not directly supporting the core technology.
- What was the total amount raised by Microbot Medical through four recent registered direct offerings by June 2023?
- By June 2023, Microbot Medical Inc. raised a total of approximately $7.6 million in gross proceeds from four recent registered direct offerings.
- What was the purpose of the $440,000 grant Microbot Medical received in June 2023?
- In June 2023, Microbot Medical Inc. received a $440,000 grant to support the development of the manufacturing process for its endovascular surgical robotic system.
Team · 13
Harel Gadot
Founder · CEO, President and Chairman
Simon Sharon
Chief Technology Officer and General Manager, Microbot Israel
Rachel Vaknin
Chief Financial Officer and Principal Accounting Officer
Juan Diaz-Cartelle, MD
Chief Medical Officer
Tal Wenderow
Independent Director
Aileen Stockburger
Independent Director
Scott R. Burell
Independent Director
Prattipati Laxminarain
Independent Director
Martin J. Madden
Independent Director
David J. Wilson
Independent Director
Michal Ahuvia
Director of Operations
Allison Rosefort
VP, Marketing
Lisa Dobbins
Director, Human Resources
Sectors & technology
Primary sector
Medical Equipment
Technologies
Target customers
Business model
Hardware Sales
Highlights
1 Patents
Tags
gastroenterologyvascularroboticsminimally-invasiveneurologyendoscopycolonoscopyurologydrug-deliveryimagingmedical-deviceshospitalsdoctorsoptronicsneurovascularmedical-equipmenttelemedicinemedical-technologiescardiovascular
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | microbotmedical.com |
|---|---|
| linkedin.com/company/1502003 | |
| facebook.com/microbotmedical | |
| YouTube | youtube.com/channel/UCXvfiDfCv_R5mDSiyEacsvg |
Identifiers & details
| Legal name | Microbot Medical Inc. |
|---|---|
| Founded | 2010 |
| Employees (exact) | 58 |
| Offices | Braintree |
| Market cap | $134.3M |
| Status reason | Public on NASDAQ on Nov 2016; |
Acquisitions & public offerings
| Acquired | Date | Amount |
|---|---|---|
| NitiLoop | 2022-10 | |
| CardioSert | 2018-05 | $370K |
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| IPO | 1992-03 | NASDAQ | MBOT | |
| Registered Direct Offering | 2019-01 | NASDAQ | MBOT | $2.5M |
| Registered Direct Offering | 2024-06 | NASDAQ | MBOT | $2.4M |
| Registered Direct Offering | 2025-01 | NASDAQ | MBOT | $11.8M |
| Stock Issuance | 2025-08 | NASDAQ | MBOT | $8.6M |
| Follow-on Offering | 2025-09 | NASDAQ | MBOT | $25.2M |
| Follow-on Offering | 2025-10 | NASDAQ | MBOT | $29.2M |
Radar intelligence
Patents
| EPO | 20 |
|---|
Web history (Wayback)
| Domain | microbotmedical.com |
|---|
Certificate / subdomain footprint
| Subdomains | 22 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514519412 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2010-11-10 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 1 |
| Registry events | 5 — annual_report (4), charge (1) |
| Registered address | היזמה 6 יקנעם עילית |
Recent registry events
| Date | Event |
|---|---|
| 2025-10-20 | דו~ח שנתי-הוספת בעל תפקיד |
| 2025-10-20 | דו~ח שנתי-שינוי בהוראות בתקנון |
| 2025-10-20 | דו~ח שנתי-הסרת בעל תפקיד |
| 2025-10-20 | דו~ח שנתי-עדכון מען דיגיטלי |
| 2026-02-02 | רישום שעבוד |